PH12016502039A1 - Potent and selective inhibitors of hepatitis c virus - Google Patents

Potent and selective inhibitors of hepatitis c virus

Info

Publication number
PH12016502039A1
PH12016502039A1 PH12016502039A PH12016502039A PH12016502039A1 PH 12016502039 A1 PH12016502039 A1 PH 12016502039A1 PH 12016502039 A PH12016502039 A PH 12016502039A PH 12016502039 A PH12016502039 A PH 12016502039A PH 12016502039 A1 PH12016502039 A1 PH 12016502039A1
Authority
PH
Philippines
Prior art keywords
virus
hepatitis
potent
selective inhibitors
compounds
Prior art date
Application number
PH12016502039A
Other languages
English (en)
Inventor
Steven J Coats
Whitaker Richard Anthony
Mcbrayer Tamara Rosario
Shi Junxing
Amblard Franck
Zhang Hongwang
Zhou Longhu
Raymond F Schinazi
Original Assignee
Univ Emory
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cocrystal Pharma Inc filed Critical Univ Emory
Publication of PH12016502039A1 publication Critical patent/PH12016502039A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH12016502039A 2014-04-15 2016-10-12 Potent and selective inhibitors of hepatitis c virus PH12016502039A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
PH12016502039A1 true PH12016502039A1 (en) 2017-01-09

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016502039A PH12016502039A1 (en) 2014-04-15 2016-10-12 Potent and selective inhibitors of hepatitis c virus

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11752166B2 (en) 2018-05-09 2023-09-12 Cocrystal Pharma, Inc. Combination therapy for treatment of HCV
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715839C (en) * 2008-02-13 2014-12-09 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
BRPI1005401A2 (pt) * 2009-02-06 2019-04-02 Rfs Pharma, Llc pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2809261A1 (en) * 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
AU2011323658A1 (en) * 2010-11-01 2013-05-23 Genoscience Pharma Novel specific HCV NS3 protease inhibitors

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
BR112016023833A2 (pt) 2017-10-10
JP2017513852A (ja) 2017-06-01
IL248318A0 (en) 2016-11-30
WO2015160907A2 (en) 2015-10-22
AU2015247706A1 (en) 2016-10-27
WO2015160907A3 (en) 2016-12-01
MX2016013434A (es) 2017-03-03
US20170029407A1 (en) 2017-02-02
CN106661004A (zh) 2017-05-10
EP3131892A2 (en) 2017-02-22
KR20170002407A (ko) 2017-01-06
CA2945514A1 (en) 2015-10-22
US9926295B2 (en) 2018-03-27
EP3131892A4 (en) 2017-09-20
RU2016144076A (ru) 2018-05-16

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
ZA201606320B (en) Human plasma kallikrein inhibitors
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
NZ703064A (en) Inhibitors of hepatitis c virus
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MX2018011786A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors